Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data

杜瓦卢马布 医学 胆道癌 吉西他滨 内科学 顺铂 胆道 肿瘤科 真实世界数据 胰腺癌 胃肠病学 癌症 化疗 计算机科学 数据科学 无容量 免疫疗法
作者
Margherita Rimini,Lorenzo Fornaro,Sara Lonardi,Monica Niger,Daniele Lavacchi,Tiziana Pressiani,Jessica Lucchetti,Guido Giordano,Andrea Pretta,Emiliano Tamburini,Chiara Pirrone,Ilario Giovanni Rapposelli,Anna Diana,Erika Martinelli,Ingrid Garajovà,Francesca Simionato,Marta Schirripa,Vincenzo Formica,Caterina Vivaldi,Enrico Caliman,Mario Domenico Rizzato,Valentina Zanuso,Federico Nichetti,Lorenzo Angotti,Matteo Landriscina,Mario Scartozzi,Matteo Ramundo,Alessandro Pastorino,Bruno Daniele,Noemi Cornara,Mara Persano,Eleonora Gusmaroli,Riccardo Cerantola,Francesca Salani,Francesca Ratti,Luca Aldrighetti,Stefano Cascinu,Lorenza Rimassa,Lorenzo Antonuzzo,Andrea Casadei‐Gardini
出处
期刊:Liver International [Wiley]
卷期号:43 (8): 1803-1812 被引量:43
标识
DOI:10.1111/liv.15641
摘要

Abstract Background The TOPAZ‐1 phase III trial reported a survival benefit with the anti‐programmed death cell ligand 1 (anti‐PD‐L1) durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer. The present study investigated the efficacy and safety of this new standard treatment in a real‐world setting. Methods The analysed population included patients with unresectable, locally advanced or metastatic adenocarcinoma of the biliary tract treated with durvalumab in combination with gemcitabine and cisplatin at 17 Italian centres. The primary endpoint of the study was progression‐free survival (PFS), whereas secondary endpoints included overall survival (OS), overall response rate (ORR) and safety. Unadjusted and adjusted hazard ratios (HRs) by baseline characteristics were calculated using the Cox proportional hazards model. Results From February 2022 to November 2022, 145 patients were enrolled. After a median follow‐up of 8.5 months (95% CI: 7.9–13.6), the median PFS was 8.9 months (95% CI: 7.4–11.7). Median OS was 12.9 months (95% CI: 10.9–12.9). The investigator‐assessed confirmed ORR was 34.5%, and the disease control rate was 87.6%. Any grade adverse events (AEs) occurred in 137 patients (94.5%). Grades 3–4 AEs occurred in 51 patients (35.2%). The rate of immune‐mediated AEs (imAEs) was 22.7%. Grades 3–4 imAEs occurred in 2.1% of the patients. In univariate analysis, non‐viral aetiology, ECOG PS >0 and NLR ≥3 correlated with shorter PFS. Conclusion The results reported in this first real‐world analysis mostly confirmed the results achieved in the TOPAZ‐1 trial in terms of PFS, ORR and safety.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
keyanxiaobai完成签到,获得积分10
2秒前
二十二点36完成签到,获得积分10
2秒前
量子星尘发布了新的文献求助10
3秒前
英勇星月完成签到 ,获得积分10
6秒前
zgt01发布了新的文献求助10
6秒前
新德里梅塔洛1号完成签到,获得积分20
9秒前
12秒前
wp完成签到,获得积分10
17秒前
splemeth完成签到,获得积分10
17秒前
雪白的紫翠完成签到 ,获得积分10
18秒前
哈哈完成签到,获得积分10
19秒前
淡定访琴完成签到,获得积分10
21秒前
大力云朵完成签到,获得积分10
23秒前
ADcal完成签到 ,获得积分10
23秒前
23秒前
tony完成签到,获得积分10
23秒前
苏苏完成签到,获得积分10
25秒前
WuFen完成签到 ,获得积分10
26秒前
淘宝叮咚完成签到,获得积分10
26秒前
高高从云完成签到 ,获得积分10
27秒前
情怀应助唐唐采纳,获得10
28秒前
科研肥料完成签到,获得积分10
29秒前
每天都在找完成签到,获得积分10
29秒前
桐桐应助zzw采纳,获得20
29秒前
29秒前
吕布完成签到,获得积分10
30秒前
30秒前
ChenYifei完成签到,获得积分10
34秒前
qq发布了新的文献求助10
34秒前
Smiley完成签到 ,获得积分10
37秒前
hzauhzau完成签到 ,获得积分10
37秒前
白桃完成签到 ,获得积分10
39秒前
小八统治世界完成签到 ,获得积分10
40秒前
Lotus完成签到,获得积分10
40秒前
btyyl完成签到,获得积分10
41秒前
屈岂愈发布了新的文献求助10
42秒前
43秒前
HH发布了新的文献求助10
44秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022